Peptide-based Cardiovascular Therapeutics Market
Peptide-based Cardiovascular Therapeutics Market By Drug (Bivalirudin, Eptifibatide), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & By Region (North America, Europe, Asia Pacific) - Global Market Insights 2023 to 2033
Analysis of Peptide-based Cardiovascular Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Peptide-based Cardiovascular Therapeutics Market Outlook (2023 to 2033)
The global peptide-based cardiovascular therapeutics market is valued at US$ 2.2 billion in 2023 and is predicted to reach US$ 4.1 billion by 2033-end. Global demand for peptide-based cardiovascular therapeutics is forecasted to increase at a CAGR of 6.4% from 2023 to 2033.
- The bivalirudin drug accounts for a market share of 60% and its use is expected to increase rapidly at a CAGR of 6.7% over the decade.
Demand for bivalirudin is expanding briskly as a result of the increasing aging population, poor lifestyle choices, and increased public awareness about the need for early heart disease detection and treatment.
Cardiovascular diseases are a major cause of death and morbidity worldwide and are treated using therapeutic peptides. Peptides are differentiated from proteins based on size, and peptides contain 50 amino acids or less, approximately. There is a growing realization of the serious effects that cardiovascular disorders have on human health. Some modern lifestyle patterns raise the possibility that a large proportion of the world's population may suffer cardiovascular ailments.
Increasing healthcare expenditure and increasing FDI in emerging economies are expected to drive the market for peptide-based cardiovascular therapeutics. The growing prevalence of cardiovascular disorders, the emergence of prominent pharmaceutical and biotech companies, and strong R&D in the development of new peptides are fueling market growth.
High incidence of hypertension among people has increased the risk of cardiovascular diseases, which supports the growth of the market for peptide-based cardiovascular therapeutics. Cardiovascular irregularities are detected in many persons, which boosts sales and supply of associated medications.
The treatment of numerous heart-related dysfunctions using cardiovascular medications is very beneficial. One of the main factors driving the growth of the market for cardiovascular medications is the increased incidence of heart disease and stroke. Due to multiple modifications to modern living, the prevalence of cardiovascular disorders has been steadily rising around the globe.
Stress, unhealthy eating habits, excessive alcohol use, sedentary lifestyles, and smoking are among the causes of a rise in cardiovascular diseases among young people. The chances of cardiovascular problems have grown among young people from emerging economies due to their extended work hours.
Cardiovascular disorders, including coronary artery disease and hyperlipidemia that causes hypertension, are also increasing heart failures and myocardial infractions. Individuals who have hyperlipidemia are more likely to develop cardiovascular disorders. The market is bolstered by emerging trends, such as the rise in the management and treatment of various cardiac illnesses, such as arrhythmia.
Rise in cardiovascular health awareness and the resulting rise in product introductions are some of the major forces driving the growth of the global cardiovascular medications market. The global market has enormous growth potential due to a rise in diabetic patients.
Market Size (2023)
US$ 2.2 Billion
Projected Market Value (2033)
US$ 4.1 Billion
Global Market Growth Rate (2023 to 2033)
Market Share of Bivalirudin (2023)
Key Companies Profiled
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is Paving the Way for Manufacturers of Peptide-based Cardiovascular Therapeutic Products?
“Increase in Related Research and Development Activities”
The market for peptide-based cardiovascular therapeutics is anticipated to rise throughout the projection period as a result of ongoing R&D of novel peptide-based medicines. Companies engage in major R&D projects to create innovative pharmaceuticals with greater efficacy in the treatment of cardiovascular illnesses and maintain their position in the market.
Obesity, elevated lipids, blood glucose, and blood pressure levels are signs of people who are at risk of cardiovascular disease. Novel peptide-based therapeutics have been introduced as a result of growing awareness of heart disorders and increased research and development of advanced therapies.
- According to the National Center for Biotechnology Information, peptide formation is receiving more attention in pharmaceutical research and development, and over 140 peptide-based treatments are now being tested in clinical trials.
“Rapid Innovations in Peptide Production Techniques”
Increased investments in drug discovery are boosting market expansion. Drug development for cardiovascular illnesses is the primary focus of peptide therapeutics research and development. The presence of a solid product pipeline is one of the factors projected to drive market growth.
Rapid innovations in peptide production techniques are anticipated to support the continued development of therapeutics. Due to the efforts made by numerous businesses to look into the creation of novel drug candidates, the market is anticipated to expand profitably throughout the projection period.
An increase in clinical trials for peptide-based cardiovascular therapeutics is supporting market expansion. The market is expected to be driven by the growing incidence of cardiovascular illnesses and the increased need for efficient therapies.
“Rising Prevalence of Cardiovascular Diseases in Geriatric Population”
Global demand for peptide-based cardiovascular therapeutics is increasing as a result of the rising prevalence of cardiovascular diseases in the geriatric population. Certain cardiovascular conditions only respond to palliative care and cannot be treated completely. This has led to a significant rise in the use of cardiovascular therapeutics. Individuals with cardiovascular illnesses are increasing as a result of the main issues of hypertension and cholesterol. This is pushing market expansion.
How is Industry Growth Being Restrained to Some Extent?
“Strict Regulations for Drug Approval and High Cost of Drug Development”
Increasing costs of commercialization, the rapid metabolism of peptide drugs, and regulatory conditions are expected to hamper market growth. Market expansion is anticipated to be constrained by the confusion regarding peptide therapeutics, the high costs of drug development, and strict regulations for drug approval.
Market expansion is hampered by a lack of public awareness of healthcare services and the side effects of specific peptide-based cardiovascular therapeutics. The various regulations the government has established surrounding the expiration of necessary medications have made it difficult for the industry to expand.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Role are Start-ups Playing in This Industry?
“New Market Entrants Offering Innovative Therapeutics for Cardiovascular Disorders”
Cardiovascular disorders are the leading cause of mortality in the world. New companies are offering innovative therapeutics for cardiovascular disorders. They are working on research and development to provide cardiovascular disease monitoring and diagnostic devices and medications to diagnose and treat cardiac problems.
- Peptide therapeutics are provided by a start-up based in Denmark, Danish ResoTher Pharma to treat cardiovascular diseases. As a form of resolution treatment, the business creates peptide-based medications from the endogenous immunomodulator Annexin A1. The medication works by imitating the body's natural ability to reduce inflammation and start the healing of damaged tissue. Moreover, the startup's peptide-based therapeutics provide treatments for conditions in which neutrophil-driven inflammation plays a significant pathological role.
Which Region is Predicted to Lead Market Expansion Going Forward?
“Increase in Approvals for Therapeutic Peptides in North America”
- North America accounts for 50% share of the global market in 2023.
An increase in approvals for therapeutic peptides is driving market growth in the region. The market is expected to develop over the forecast period as a result of the introduction of new products, rising research and development activities, and elevated risk factors, including diabetes in the general population.
Market growth is attributed to the presence of several market participants, and the introduction of numerous innovative medications. The rising prevalence of hypertension in the population, the availability of upscale medical facilities, favorable regulatory environment are driving market expansion.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Will the United States Be a Lucrative Market for Key Industry Players?
“Presence of Developed Healthcare Infrastructure to Provide Great Opportunities”
Market growth in the United States is driven by significant government investments in peptide drug discovery. The market in the United States is anticipated to experience significant expansion over the projection period due to a rise in the local supply of peptide-based cardiovascular therapeutics. The market is driven by the presence of a developed healthcare infrastructure.
Why Should Suppliers of Peptide-based Cardiovascular Therapeutics Target Germany?
“Noteworthy Rise in Healthcare Spending”
The growing geriatric population is driving the demand for peptide-based cardiovascular therapeutics in Germany. The market is expanding as a result of the availability of advanced medications for cardiovascular disease treatments. Growing awareness of heart-related issues, an increase in healthcare spending, and a rise in R&D centers are boosting market value in the United States.
How is Japan Contributing to Revenue Generation in Asia Pacific?
“Rapid Expansion of Biotech Industry”
The market value in Japan is anticipated to increase due to the growing prevalence of cardiovascular disorders, rising demand for heart attack diagnostics, a thriving biotech industry, and an increase in clinical trials. An increase in obesity among the population due to unhealthy lifestyles and the robust pharmaceutical industry plays a significant role in market expansion.
Why is Demand for Bivalirudin Increasing Rapidly?
“Bivalirudin Preferred to Reduce Need for Bypass Surgeries”
By drug, the market is classified into bivalirudin and eptifibatide. Bivalirudin holds 60% share of the global market at present.
Bivalirudin is an anticoagulant that aids in preventing the development of blood clots, particularly in those who are having angioplasty or have significant chest discomfort. Only IV usage of bivalirudin is permitted, and it is provided in sterile, lyophilized form in glass vials. Bivalirudin is widely used in conjunction with other drugs. The medication is often regarded as a secure and reliable anticoagulant to reduce the need for bypass surgeries.
Increasing prevalence of cardiovascular disorders boosting the use of bivalirudin. Bivalirudin is expected to be increasingly used in anticoagulant therapy during the forecast period as a consequence of its various benefits, which include fewer bleeding problems and improved clinical outcomes.
Which Distribution Channel is Leading the Sales of Peptide-based Cardiovascular Therapeutics?
“Hospital Pharmacies Gaining Traction Since Peptide-based Cardiovascular Therapeutics Usually Prescribed after Thorough Diagnosis”
The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies based on the distribution channel.
- Sales of peptide-based cardiovascular therapeutics through hospital pharmacies are anticipated to increase at a CAGR of 8% during the forecast period.
Hospital pharmacies are gaining traction because peptide-based cardiovascular therapeutics are usually prescribed after a thorough diagnosis. Easy access to both rare and routinely used medications is boosting the sales of peptide-based cardiovascular therapeutics through hospital pharmacies.
Hospital pharmacies have easy access to emergency cardiovascular medications. Hospital pharmacists widely dispense both therapeutic and diagnostic drugs for cardiovascular illnesses.
Key market players are focusing on new developments, product releases, quality control, and partnerships between hospitals & pharmaceutical companies. They are investing heavily in R&D initiatives for the creation of innovative therapeutics while following safety regulations.
Major market participants are exploring innovative methods and discovering new formulations. They are concentrating on product standards, the regulatory environment, supply chain management, and pricing trends.
Top manufacturers of peptide-based cardiovascular therapeutics are focusing on market expansion through distribution agreements, partnerships, and research into untapped markets. To strengthen their local presence and expand their manufacturing capabilities, established enterprises are now collaborating with regional businesses.
- In 2019, Anthos Therapeutics was established by Novartis AG and Blackstone's Lifesciences and is crucial to the creation of cardiovascular therapeutics. This would provide the company with an advantage in the market and accelerate market expansion throughout the forecast period.
Key Segments of Peptide-based Cardiovascular Therapeutics Industry Research
By Drug :
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region :
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- FAQs -
The global peptide-based cardiovascular therapeutics market is valued at US$ 2.2 billion in 2023.
By 2033, the market for peptide-based cardiovascular therapeutics is expected to reach a valuation of US$ 4.1 billion.
Demand for peptide-based cardiovascular therapeutics is forecasted to rise at a CAGR of 6.4% through 2033.
AstraZeneca plc, Corden Pharma GmbH, and Ipsen are the top suppliers of peptide-based cardiovascular therapeutic products.
North America currently accounts for 50% share of the global peptide-based cardiovascular therapeutics market.